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Abstract 1 
Murine IgG3 glycan-targeting mAb often induces direct cell killing in the absence of immune effector 2 
cells or complement via a proinflammatory mechanism resembling oncotic necrosis. This cancer cell 3 
killing is due to non-covalent association between Fc regions of neighboring antibodies, resulting in 4 
enhanced avidity. Human isotypes do not contain the residues underlying this cooperative binding 5 
mode; consequently, the direct cell killing of mouse IgG3 mAb is lost upon chimerization or 6 
humanization. Using the Lewis
a/c/x 
-targeting 88mAb, we identified the murine IgG3 residues 7 
underlying the direct cell killing and increased avidity via a series of constant region shuffling and 8 
subdomain swapping approaches to create improved ('i') chimeric mAb with enhanced tumor killing in 9 
vitro and in vivo. Constant region shuffling identified a major CH3 and a minor CH2 contribution, 10 
which was further mapped to discontinuous regions among residues 286-306 and 339-378 that, when 11 
introduced in 88hIgG1, recapitulated the direct cell killing and avidity of 88mIgG3. Of greater interest 12 
was the creation of a sialyl-di-Lewis
a
 -targeting i129G1 mAb via introduction of these selected 13 
residues into 129hIgG1, converting it into a direct cell killing mAb with enhanced avidity and 14 
significant in vivo tumor control. The human iG1 mAb, termed Avidimabs, retained effector functions, 15 
paving the way for the proinflammatory direct cell killing to promote ADCC and CDC through relief of 16 
immunosuppression. Ultimately, Fc engineering of human glycan-targeting IgG1 mAb confers 17 
proinflammatory direct cell killing and enhanced avidity, an approach that could be used to improve 18 
the avidity of other mAb with therapeutic potential. 19 
Statement of Significance 20 
Fc-engineering enhances avidity and direct cell killing of cancer-targeting anti-glycan antibodies to 21 
create superior clinical candidates for cancer immunotherapy. 22 
 23 
  24 
Introduction 1 
The cancer glycome is a rich source of targets for monoclonal antibody (mAb) development due to 2 
the alterations associated with the transformation process, as well as glycans being key co-accessory 3 
molecules for cancer cell survival, proliferation, dissemination and immune evasion (1,2). A number of 4 
anti-glycan mAbs are in clinical development, as passive or active immunotherapy or reformatted for 5 
chimeric antigen receptor (CAR) T cells (3-5).  Additionally, Dinutuximab beta, an anti-GD2 mAb, is 6 
currently used for the treatment of neuroblastoma (6).   7 




 (7,8) as well 8 
as sialyl-di-Lewis
a 
reactivity (9). Intriguingly, some of these glycan-binding mAbs exhibited a direct 9 
cytotoxic effect on high-density target expressing cancer cells, independent of the presence of 10 
complement or immune effector cells. This direct cytotoxic ability has also been observed for other 11 
anti-glycan mAbs and typically involves mAb-induced homotypic cellular adhesion, cytoskeletal 12 
rearrangement followed by cell swelling, membrane lesions and eventual cellular demise (7,10-13). In 13 
most cases the cell death is a form of non-classical apoptosis, potentially involving the generation of 14 
reactive oxygen species (ROS), and most closely resembling oncotic necrosis (14,15). Importantly, 15 
akin to immunogenic or inflammatory cell death (ICD), the coinciding release of in inflammatory 16 
mediators - damage associated molecular patterns (DAMPs) - has the potential to recruit innate 17 
immune cells to the tumor site that may further increase mAb-mediated effector functions (16). Thus, 18 
these anti-glycan mAbs can be important tools to remobilise the full potential of the immune system in 19 
an otherwise immunosuppressive environment.  20 
The direct killing ability of anti-glycan mAbs is mediated by murine (m) IgG3, an isotype that exhibits 21 
non-covalent interactions between adjacent Fc regions, thereby increasing avidity, via prolonging 22 
target occupancy; a process termed “intermolecular co-operativity” (17,18). In humans, the IgG2 23 
isotype can increase avidity via dimerization involving one or more Cys residues in its hinge region 24 
(19). However, this inefficient process, combined with poor ADCC and CDC activity render the hIgG2 25 
an unattractive clinical candidate.  26 
Our panel of mAbs induce strong in vitro and in vivo tumor killing in preclinical mouse models (7,8) 27 
and thus are candidates for clinical development. Chimerization of the mIgG3 mAbs onto a human 28 
IgG1 backbone coincided with a dramatic reduction in direct cytotoxicity, leading us to hypothesize 29 
that this was the result of diminished intermolecular cooperativity. Consequently, the rationale for this 30 
study was to identify the key residues within mIgG3 that are responsible for non-covalent Fc 31 
interactions and transfer them into hIgG1 in order to recapitulate the mIgG3-observed direct 32 
cytotoxicity and avidity, thereby creating a chimeric hIgG1 with superior clinical utility.  33 
We report here the identification of discontinuous regions within the mIgG3 CH2 and CH3 domains 34 
that endow this isotype with direct cytotoxicity and increased avidity. Transfer of these residues into 35 




Methods  2 
Materials, cells and antibodies 3 
Colorectal cancer cell lines (COLO205 and HCT15) as well as the murine myeloma NS0 cell line were 4 
purchased from ATCC (Virginia, USA). All cell lines were authenticated using short tandem repeat 5 





 were from IsoSepAB (Sweden).  Cell lines were maintained in 7 
RPMI medium 1640 (Sigma) supplemented with 10% fetal calf serum, L-glutamine (2mM) and sodium 8 
bicarbonate-buffered. Parental murine FG88.2 and FG129 mAbs were generated, as previously 9 
described (7);(9)). 10 
Cloning of modified mAb constructs 11 
In order to create chimeric hIgG1 variants of our hybridoma-produced mAbs (FG88.2 and FG129), the 12 
heavy chain and light chain variable regions encoding the respective mAbs were introduced into the 13 
pDCOrig vector using the restriction enzymes BamHI/BsiWI (light chain locus) or HindIII/AfeI (heavy 14 
chain locus) (20). The synthetic heavy chain constant regions (CH), including full mIgG3 constant 15 
regions as well as interchanged mIgG3-hIgG1 domains and single residue changes, were designed 16 
and ordered from Eurofins MWG (Ebersberg, Germany). Typically, this involved a 1054bp cassette 17 
supplied in proprietary Eurofins vectors, stretching from the AfeI restriction site at the VH/CH junction 18 
to an XbaI site 3’ to the CH stop codon. After maxiprep (Qiagen), 15µg of plasmid DNA was digested 19 
with AfeI and XbaI (NEB) and the insert gel-purified (QIAquick, Qiagen) and introduced into AfeI/XbaI 20 
digested vector pOrigHiB (20) by ligation (T4 DNA ligase, NEB). Following sequence confirmation, 21 
15µg of plasmid DNA was digested with AfeI and AvrII (NEB) and the insert introduced into AfeI/AvrII 22 
digested vector pDCOrig by ligation. A cartoon representation of the key Fc-engineered constructs is 23 
shown in Supplementary Fig. 5. 24 
HEK293 transfection and mAb purification  25 
mAb constructs were obtained following transient transfections of Expi293F™ cells using the 26 
ExpiFectamine™ 293 Transfection kit (Gibco, LifeTechnologies).  Briefly, HEK293 cells in suspension 27 
(100ml, 2x10
6
/ml) were transfected with 100µg DNA and conditioned medium harvested at day seven 28 
post-transfection.  mAb-containing supernatant was filtered through 0.22µm bottle top filters (Merck 29 
Millipore) and sodium azide added to a final concentration of 0.2% (w/v). mAb was purified on protein 30 
G columns (HiTrap ProteinG HP, GE Healthcare) using an AKTA FPLC (GE Healthcare). Columns 31 
were washed with PBS/Tris buffer (PBS with 50mM Tris/HCl, pH7.0) before mAb elution with a rapid 32 
gradient into 100mM glycine, pH12 (supplemented with 0.05% v/v Tween 20), collecting 2ml fractions. 33 
Fractions containing mAb were pooled, neutralized to pH 7.0 (using 1M HCl) and dialyzed against 34 
PBS, before concentration determination and storage at -80°C. All transiently expressed mAb 35 
constructs were analyzed for cell binding using flow cytometry, as a read-out for correct folding, and 36 
compared to the parental 88mIgG3 and 88hIgG1, prior to use in functional assays. 37 
Indirect immunofluorescence and flow cytometry 38 
Cancer cells (1x10
5
) were incubated with primary mAbs (at 33.3nmol/L or titrated) for 1h at 4°C, as 39 
previously described (7) followed by 1h incubation at 4°C with anti-mouse or anti-human FITC-40 
labelled secondary antibody, and fixing in 0.4% formaldehyde. Stained samples were analyzed on a 1 
MACSQuant 10 flow cytometer and analyzed using FlowJo v10. 2 
Avidity determination 3 
The kinetic parameters of the 88 and 129 mAbs binding to Lewis
a
 - or sialyl-Lewis
a
 -APD-HSA were 4 
determined by Surface Plasmon Resonance (SPR, Biacore 3000, GE Healthcare). Increasing 5 
concentrations (0.3nmol/L-200nmol/L) of mAb were injected across a CM5 chip and data were fitted 6 
to a heterogeneous ligand binding model using BIAevaluation 4.1.  The chip contained four cells, two 7 
of which, HSA-coated (in-line reference cells), the other two were coated with low (30-80 response 8 
units (RU)) and high amounts (360-390 RU) of the respective glycan-APD-HSA. 9 
In vitro cytotoxicity 10 
Propidium Iodide (PI) uptake and proliferation inhibition were performed to analyze the direct cytotoxic 11 
effect of the mAbs.  COLO205 or HCT15 cells (5 x 10
4
) were incubated with mAbs for 2h at 37°C 12 
followed by the addition of 1µg of PI for 30min.  Cells were resuspended in PBS and run on a 13 
Beckman Coulter FC-500 or on a MACSQuant 10 flow cytometer and analyzed with WinMDI 2.9 or 14 
FlowJo v10 software, respectively.  Proliferation inhibition was assessed by using the water-soluble 15 
tetrazolium salt WST-8 (CCK8 kit, Sigma-Aldrich) to measure the activity of cellular hydrogenases 16 
which is directly proportional to the number of viable cells. Briefly, after overnight plating of cancer 17 
cells (1000 cells/90µl/well), constructs were added at different concentrations in a final volume of 18 
10µl/well and the plates were incubated at 37°C, (5%CO2) for 72-96h. WST-8 reagent was then 19 
added (10µl/well) and after a further 3h incubation, the plates were read at 450nm (Tecan Infinite F50) 20 
and percentage inhibition calculated. EC50 values were determined using nonlinear regression (curve 21 
fit) with GraphPad Prism v 8.0 (GraphPad Inc, La Jolla, CA). 22 
Immune effector function determination 23 
ADCC and CDC were performed as described previously (7). 
51
Cr-labeled target cells (5 × 10
3
) were 24 
co-incubated with 100μL of peripheral blood mononuclear cells (PBMC) from healthy donors (ADCC) 25 
or 10% (v/v) autologous serum (CDC) and with mAbs at a range of concentrations; the effector to 26 
target ratio was 100:1 (E:T)). Spontaneous and maximum release [counts per minute (cpm)] were 27 
evaluated by incubating the labelled cells with medium or with 10% (v/v) Triton X-100, respectively. 28 
The mean percentage lysis was calculated as follows: mean % lysis = (experimental cpm - 29 
spontaneous cpm)/(maximum cpm − spontaneous cpm) × 100. 30 
Scanning electron microscopy 31 
HCT15 or COLO205 cells (1 x 10
5
) were grown on sterile coverslips for 24h prior to mAb (0.2µmol/L) 32 
addition for 18h at 37°C.  Controls included medium alone and 0.5% (v/v) hydrogen peroxide (H2O2) 33 
(Sigma). Cells were washed with pre-warmed 0.1 M sodium cacodylate buffer pH7.4 (SDB) and fixed 34 
with 12.5% (v/v) glutaraldehyde for 24h. Fixed cells were washed twice with SDB and post-fixed with 35 
1% (v/v) osmium tetroxide (pH 7.4) for 45min.  After a final wash with H2O, the cells were dehydrated 36 
in increasing concentrations of ethanol and exposed to critical point drying, before sputtering with 37 
gold, prior to SEM analysis (JSM-840 SEM, JEOL). 38 
Recombinant human FcRn binding analysis 39 
The ability of the mAbs to bind to recombinant human (rh) FcRn (R&D Systems) was evaluated using 1 
direct ELISA at pH6.0 and pH7.0.  Briefly, high-binding ELISA plates were coated with 250ng/well 2 
rhFcRn followed by blocking with protein-free blocking buffer (Thermo Fisher Scientific). Primary mAb 3 
dilutions (in phosphate buffer pH6.0 or pH7.0) were added (1h at room temperature), followed by 4 
washing with respective phosphate buffers containing 0.05% (v/v) Tween 20, and detection of bound 5 
mAbs with goat F(ab)2 anti-human IgG(Fab)2 HRP antibody (Abcam).  The anti-hCTLA4 hIgG1 mAb 6 
Ipilimumab (clinical grade) was included as a positive control. 7 
Biophysical characterization of the mAbs (size exclusion chromatography with multi-angle 8 
light scattering (SEC-MALS) and analytical ultracentrifugation (AUC)) 9 
SEC-MALS experiments were performed using a Superose 6 10/300 Increase column (GE 10 
Healthcare) on an AktaPure 25 System (GE Healthcare). mAb samples (100μL at 1mg/mL), were 11 
loaded and eluted with one column volume (24mL) of buffer, at a flow rate of 0.5mL/min. The eluting 12 
protein was monitored using a DAWN HELEOS-II 18-angle light scattering detector (Wyatt 13 
Technologies) equipped with a WyattQELS dynamic light scattering module, a U9-M UV/Vis detector 14 
(GE Healthcare), and an Optilab T-rEX refractive index monitor (Wyatt Technologies). Data were 15 
analyzed by using Astra (Wyatt Technologies) using a refractive index increment value of 0.185mL/g.  16 
For AUC characterization, sedimentation velocity scans were recorded for each mAb sample at 17 
concentrations of 5.0, 2.5 and 0.5μmol/L. All experiments were performed at 50,000 rpm, using a 18 
Beckman Optima analytical ultracentrifuge with an An-50Ti rotor at 20˚C. Data were recorded using 19 
the absorbance optical detection system at 280nm. The density and viscosity of the buffer was 20 
measured experimentally using a DMA 5000M densitometer equipped with a Lovis 200ME viscometer 21 
module. The partial specific volume of the antibodies was calculated using SEDFIT from the amino 22 
acid sequence. Data were processed using SEDFIT, fitting to the c(s) model. Figures were made 23 
using GUSSI. 24 
C4d ELISA 25 
Complement activation in normal human serum, in the absence of target, was determined by 26 
measuring C4d concentrations, a marker for classical complement pathway activation.  mAbs (10% 27 
v/v, 100μg/mL) were incubated in 90% normal human serum (three healthy donors) for 1 h at 37°C. 28 
C4d concentrations were measured using a commercial ELISA kit (MicroVue C4d EIA kit, Quidel 29 
Corporation, San Diego, US) according to the manufacturer’s instructions.  Heat-aggregated (HA) 30 
mAb served as a positive control; the anti-hCTLA4 hIgG1 mAb Ipilimumab (clinical grade) as a 31 
reference. 32 
In vivo model 33 
The study was conducted and approved by CrownBio UK under a UK Home Office Licence in 34 
accordance with NCRI, LASA, and FELAS guidelines. Animal welfare for this study complies with the 35 
UK Animals Scientific Procedures Act 1986 (ASPA) in line with Directive 2010/63/EU of the European 36 
Parliament and the Council of September 22, 2010 on the protection of animals used for scientific 37 
purposes.  Subcutaneous tumors of a human colorectal adenocarcinoma model of COLO205 were 38 
established in age-matched female BALB/c nude (Charles River, UK) mice via injection of 5×10
6 39 
viable cells in 0.1ml serum free RPMI:Matrigel (1:1) into the left flank of each mouse.  Mice (n=10) 40 





on study day 6 and dosed intravenously (i.v.), biweekly, with mAbs (0.1mg) or vehicle (PBS, 100µl) up 2 
until week 5.  Body weight and tumor volume were assessed three times weekly and reduction in 3 
tumor volume analyzed statistically using two-way ANOVA with Bonferroni’s post-test at day 35, when 4 
all control animals were still in the study (GraphPad Prism v 7.4, GraphPad Inc, La Jolla, CA). 5 
Statistical analyses 6 
The error bars shown in the figures represent the mean ± SD.  Titration curves for functional assays 7 
(direct cell killing, immune effector functions) were analyzed with two-way ANOVA with the construct 8 
factor P values graphed. Functional affinity results as well as fixed-concentration functional assays 9 
were analyzed with one-way ANOVA with Dunnett’s corrections for multiple comparisons.  All 10 
analyses were performed with GraphPad Prism v 7.4 (GraphPad Inc, La Jolla, CA), with * P ≤ 0.05, ** 11 
P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 12 
  13 
Results 1 
m88G3 exhibits avid glycan binding as well as direct cytotoxicity in the absence of 2 
complement and immune effector cells, both of which are reduced upon chimerization to 3 
88hIgG1 4 
We have previously shown that the hybridoma-produced mIgG3 mAb FG88.2 exerts a direct 5 
cytotoxic effect on high-binding cancer cell lines, such as COLO205 and HCT15, in the absence of 6 
complement or effector cells (7). This direct cytotoxicity involved mAb-induced cellular aggregation, 7 
proliferation inhibition as well as irregular pore formation through an oncolytic mechanism. We 8 
subsequently created a chimeric, HEK293-expresssed, hIgG1 mAb, 88hIgG1, for clinical exploitation. 9 
88hIgG1 maintained equivalent HCT15 and COLO205 cancer cell binding levels (Fig. 1A), compared 10 
to the hybridoma-produced FG88.2, as well as the HEK293-expressed 88mIgG3.  The latter mAb was 11 
generated to rule out expression system related effects such as differential Fc glycosylation, due to 12 
the use of murine hybridoma cells versus HEK293 cells. Surprisingly, 88hIgG1, exhibited significantly 13 
reduced direct cytotoxicity on COLO205 and HCT15, across two functional assays, PI uptake and 14 
proliferation inhibition, compared to 88mIgG3 (Fig. 1, panels B-D). 88mIgG3 also displayed a modest 15 
reduction in direct cytotoxicity compared to the hybridoma-produced FG88.2, suggesting that 16 
differential glycosylation of the Fc region by the two expression settings (mouse hybridoma versus 17 
HEK293 cells) contributed to the effect. Combined, the results indicated that the direct cell killing 18 
could be related to the kinetic binding behaviour of the different isotypes. Consequently, the kinetic 19 
binding of our isotype-switched mAbs was analyzed on a Lewis
a
 -APD-HSA coated chip using SPR ( 20 
Supplementary Table 1). FG88.2 displayed avid Lewis
a
 -APD-HSA binding with fast apparent on-rates 21 
(kon ~ 10
4 
1/smol/L) and very slow off rates (koff ~ 10
-6 
1/s) on the high-density flow cell.  The HEK293-22 
produced 88mIgG3 exhibited an apparent faster on-rate (kon ~ x 10
5 
1/smol/L) and a somewhat faster 23 
off-rate (koff ~10
-4 
1/s) compared to FG88.2, that could explain the slightly reduced cytotoxicity 24 
compared to FG88.2.  In comparison, 88hIgG1 bound its target with an apparent fast on-rate (kon ~ 25 
10
5 
1/smol/L), but in contrast to the mIgG3 isotypes displayed a much faster dissociation phase 26 
(apparent koff ~ 10
-2
 1/s), that is likely to underly its reduced cytotoxic activity upon cancer cell binding.  27 
The mAb binding behaviour on the low-density flow cell was largely comparable between the three 28 
mAbs, with equilibrium dissociation constants (Kd) of the order of 10
-8
 mol/L for all three isotypes. 29 
 30 
Domain analysis of the mIgG3 constant region indicate a major contribution by the mIgG3 CH3 31 
domain with a minor involvement of the CH2 32 
Collectively, the results outlined above suggested that the high Lewis
a
 -APD-HSA avidity exhibited 33 
by FG88.2 and 88mIgG3, predominantly driven by their slow target dissociation and potentially 34 
resulting from the intermolecular cooperativity of the mIgG3 isotype, contributed to their direct 35 
cytotoxic effect.  We thus set out to engineer a hIgG1 cancer glycan targeting mAb with direct 36 
cytotoxic activity, via the transfer of selected mIgG3 constant region residues into 88hIgG1. Firstly, 37 
mIgG3 contributing regions were identified through the creation of hybrid 88hIgG1 constructs, 38 
containing mIgG3 CH1, CH2 or CH3 domains.  Preliminary analyses ascertained that mIgG3 CH1 39 
had a negligible contribution to the direct cytotoxicity ability of 88mIgG3, as introducing mIgG3 CH1 40 
into 88hIgG1 (1m1) did not lead to a significant increase in cytotoxicity (Fig. 2, Panels A and B). 1 
Conversely, introducing hIgG1 CH1 into 88mIgG3 (3h1), equally, did not instigate a significant 2 
reduction in killing activity (Fig. 2, Panels A and B). Next, in a gain-of-function approach, the mIgG3 3 
CH2 and CH3 domains, separately, were introduced in 88hIgG1. 88hIgG1 containing murine CH3 4 
(1m3) exhibited a significant gain in PI uptake on HCT15, as well a significant increased proliferation 5 
inhibition of COLO205 cells, when compared to 88hIgG1 (Fig. 2, Panels C and D).  Introducing 6 
murine CH2 into 88hIgG1 (1m2) led to small, but not significant, increase in killing activity across both 7 
assays (Fig. 2, Panels C and D).  As a confirmation of the contributions made by both domains, the 8 
reverse strategy was adopted, whereby a loss of cytotoxicity activity was evaluated due to the 9 
introduction hIgG1 CH2 or CH3 domains into 88mIgG3.  This scenario led to a significant decrease in 10 
cytotoxicity for 88mG3 containing hIgG1 CH3 (3h3), corroborating the previous gain-of-function 11 
results.  Importantly, this strategy also identified a small contribution by the murine CH2, as 88mIgG3 12 
containing human CH2 (3h2) exhibited a significant decrease in cytotoxicity activity (Fig. 2, Panels C 13 
and D).  Next, the kinetic binding behaviour of the hybrid constructs was analyzed. The hybrid 14 
construct 1m3 exhibited a modest, but significant increase in avidity (decreased Kd), whilst 3h3, 15 
containing human CH3, displayed a significant decrease in avidity (increased Kd, Fig. 2, Panel E), in 16 
both cases, mirroring the direct cytotoxicity. Human CH2 in construct 3h2 also led to a modest, but 17 
significant drop in avidity. In all cases, the changes in avidity were predominantly driven by changes in 18 
the off-rate of the mAbs, with 1m3 showing a significantly decreased off-rate compared to 88hIgG1, 19 
whereas 3h3, as well as 3h2, exhibited a significantly increased off-rate compared to 88mIgG3 (Fig. 20 
2, panel F).  Murine CH2 in construct 1m2 did not lead to increased avidity nor a decreased off-rate, 21 
underlying the insignificant cytotoxicity of this construct compared to 88hIgG1 (Fig. 2, panels C and 22 
D). Taken together the results indicate that the murine CH3 has a more pronounced contribution to 23 
cytotoxicity, as well as kinetic binding, whereas the contribution by murine CH2 is smaller, only 24 
observed in a loss-of-function setting. 25 
 26 
Discontinuous sequences within the CH2-CH3 region of aa 286-397 are essential for killing 27 
activity and increased avidity 28 
As the cytotoxic effect endowed by the murine CH3 was not complete, and in order to further narrow 29 
down the other contributing residues, we designed hybrid 88 mAb constructs where the CH2 and CH3 30 
domains were further subdivided into two subdomains (SD) with junction regions containing a 10 31 
residue overlap: CH2: SD232-294 and SD286-345 and CH3: SD339-397 and SD390-447.  On 32 
COLO205, both SD339-397 and SD286-345 afforded a similar significant increase in cytotoxicity, 33 
most evident at the lower concentrations, whereas SD232-294, as well as SD390-447, were 34 
dispensable for cytotoxicity (Fig. 3, panels A and C). On HCT15 however, the significant contribution 35 
by residues within SD339-397 was larger than that of SD286-345 (Fig. 3, panels B and D), suggesting 36 
that subtle differences in glyco-antigen density and composition can modulate mAb binding and 37 
ensuing cytotoxic activity. Strikingly, 88hIgG1, containing the combined mIgG3 SD286-345 and 38 
SD339-397 (SD286-397), recovered virtually all the cytotoxicity of 88mIgG3 on both cell lines and 39 
across both assays (Fig. 3, panels A-D), obviating the need for adding additional subdomains.  Avidity 40 
analysis of the subdomain constructs, compared to 88hIgG1, revealed a striking improvement in 1 
avidity for SD286-397, as well as SD339-397, both now matching the 88mIgG3 avidity, with a more 2 
modest improvement for SD286-345 (Fig. 3, Panel E).  The improved avidity resulted mainly from a 3 
dramatically reduced apparent off-rate (~10
-6
 1/s) for SD286-397 as well as SD339-397, with the 4 
SD286-345 off-rate showing a more modest improvement (~ 10
-3
 1/s) (Fig. 3, Panel F). These results 5 
add further weight to the cytotoxicity observations and support the notion that creating a mAb with a 6 
reduced target dissociation rate upholds direct cytotoxicity.  7 
Although SD339-397, with 27 mIgG3 residues, recapitulated up to 90% of the desirable attributes of 8 
88mIgG3, notably the slow dissociation and enhanced cytotoxicity, it exhibited a significantly reduced 9 
CDC activity compared to 88hIgG1 (Fig. 3, Panel G), but it maintained ADCC activity compared to 10 
88hIgG1 (Fig. 3, Panel H).  The effect on the immune effector functions thus necessitated the use of 11 
SD286-397, containing 41 mIgG3 residues for further development. Consequently, additional 12 
subdivisions of SD286-345 and SD339-397 were analyzed for cytotoxic activity and avidity in order to 13 
further reduce the number of mIgG3 residues.  Firstly, within SD339-397, SD339-378, containing 20 14 
mIgG3-specific residues, upon introduction in 88hIgG1 led to a significant regain of cytotoxicity to 15 
within ~ 80% to 90% of mIgG3 cytotoxicity across both cytotoxicity assays (Fig. 4, Panels A and B). 16 
This region, also instilled a significant increase in avidity, compared to 88hIgG1 (Fig. 4, Panel G), but 17 
this improvement was not as pronounced as in the case of SD339-397 (Fig. 3, Panel G). Immune 18 
effector functions (ADCC and CDC) of SD339-378 were not significantly different from 88hIgG1 (Fig. 19 
4, Panels H and I). Additionally, within SD286-345, the significant reduction in cytotoxicity by SD307-20 
345, compared to SD286-345, implied a further contribution by residues 286-306 (Fig. 4, Panel C). 21 
Collectively, the results suggested that a construct containing the combination of residues 286-306 22 
and 339-378, totalling 26 mIgG3-specific residues, could potentially fully recapitulate 88mIgG3 direct 23 
cytotoxicity and avidity. To test this hypothesis, the cytotoxic activity and avidity of SD286-306+339-24 
378 was evaluated. SD286-306+339-378 exhibited significantly improved direct cytotoxicity, 25 
compared to 88 hIgG1, on both cell lines, now matching 88mIgG3 cytotoxicity (Fig. 4, Panels D-F). 26 
SPR analysis of SD286-306+339-378 revealed a significantly improved avidity compared to 88hIgG1 27 
with a Kd (0.3 x 10
-9 
nmol/L) now similar to 88mIgG3 (Fig. 4, Panel G). Importantly, neither the CDC 28 
activity, nor the ADCC activity of the SD286-306+339-378 construct was significantly different from 29 
that of 88hIgG1 (Fig.4, Panels H and I). The combination of improved avidity with direct cytotoxicity, 30 
as well as maintained immune effector functions, indicates that our SD286-306+339-378 hybrid hIgG1 31 
mimics the desirable attributes of 88mIgG3.   32 
  33 
Reversal of one in silico identified MHCII binding cluster generates the lead candidate,  1 
improved ‘i’ 88G1, with robust cell killing, increased avidity, pore-forming ability and sound 2 
immune effector functions 3 
We performed an in silico screen of the SD286-306+339-378 sequence, containing 26 mIgG3 4 
residues, for MHCII binding epitopes (Immune Epitope Database, IEDB), in order to assess potential 5 
immunogenicity.  Class II-restricted T helper cells are relevant to the humoral immune response and 6 
predicted binding clusters have been shown to be strong indicators of T cell responses (21). Two 7 
potential MHCII binding clusters, were identified: cluster 1 (residues 294-315) which would be 8 
potentially immunogenic in a wide range of HLA types and cluster 2 (residues 365-393) which would 9 
potentially only be weakly immunogenic in HLA-DR*0401 and HLA-DR*01101(Supplementary Fig.1).  10 
Reversion of three murine residues, 294 (A to E), 300 (F to Y) and 305 (A to V), within cluster 1, to 11 
human residues, produced a human sequence section to which individuals would have been 12 
tolerized.  Similarly, reversal to human sequence of two residues 351 (I to L) and 371 (N to G), within 13 
cluster 2, removed two potential MHCII binding epitopes. Consequently, we created two additional 14 
SD286-306+339-378 - based constructs: DI1 and DI2, containing three and two human reverted 15 
residues, respectively, and assayed their cytotoxicity and avidity.  DI1 maintained significantly 16 
improved cytotoxicity compared to 88hIgG1. Additionally, the direct cytotoxicity coincided with a 17 
favourable avidity profile, with an apparent off-rate of (~ 10
-4
 1/s) and a Kd of 0.5 nmol/L that was 18 
similar to 88mIgG3 (Fig. 5, Panel C, Table 1 and Supplementary Fig. 2). In contrast, DI2 showed a 19 
small, but consistently decreased activity compared to 88mIgG3 (Fig. 5, Panels A and B) as well as a 20 
significantly decreased avidity compared to 88mIgG3 (Fig. 5, Panel C). As this cluster was only 21 
potentially weakly immunogenic in two HLA-DR types, these two residues have not been reverted. 22 
Instead, we focused on 88DI1, containing 23 mIgG3 residues, now renamed ‘i’ (improved) 88G1, for 23 
further analysis of its immune effector functions. 88hIgG1 showed potent ADCC activity on COLO205 24 
with sub-nanomolar EC50 (Fig. 5, panel D), in line with the potent immune effector functions of FG88.2 25 
(7). Similarly, i88G1 displayed potent ADCC with subnanomolar EC50 (0.35 nmol/L) albeit significantly 26 
reduced compared to 88hIgG1 (EC50 0.13 nmol/L).   The CDC activity of i88G1 (EC50 0.1 nmol/L) was 27 
significantly improved compared to 88hIgG1 (3.9 nmol/L) (Fig. 5 Panel E, Table 1).  28 
Earlier work on the parental hybridoma-produced FG88.2 had demonstrated its pore-forming ability, 29 
which was surmised to underlie its cytotoxicity (7). We thus set out to analyze the pore-forming ability 30 
of i88G1 on HCT15, using SEM.  Incubation of HCT15 with i88G1 or 88mIgG3, but not 88hIgG1, 31 
resulted in monolayer disruption, cell rounding and clustering.  At higher magnification, irregular pore 32 
formation was evident (Fig. 5 Panel F), mirroring the original data observed for the hybridoma-33 
produced FG88.2 (7).  34 
Collectively the results indicate that transfer of selected regions from the mIgG3 constant region into 35 
the 88higG1 backbone created a hybrid mAb with direct cell killing ability, increased avidity, pore 36 
forming ability as well as robust immune effector functions. 37 
Transfer of the ‘iG1’ sequences into an alternative, non-killing, glycan binding mAb (129 38 
hIgG1) creates a cancer-targeting mAb with significantly improved avidity and ensuing in vitro 39 
and in vivo anti-tumor activity 40 
We recently described the generation of a sialyl-di-Lewis
a
 recognizing mAb (129 mAb) with 1 
development potential for cancer immunotherapy (9).  The 129 mAb has a more favorable tumor 2 
versus normal human tissue distribution compared to the above-described 88 mAb, resulting from 3 
wide-ranging tumor tissue binding, combined with very restricted normal tissue reactivity. Neither the 4 
hybridoma-produced FG129, a murine IgG1 mAb, nor the chimeric 129hIgG1, exhibited direct 5 
cytotoxicity. This led us to test the hypothesis that the introduction of the 23 above-selected mIgG3 6 
constant region residues into the Fc region of 129hIgG1 would create an ’i’129G1 with direct 7 
cytotoxicity and improved avidity and thus exhibit superior clinical utility. 8 
We evaluated the direct cytotoxicity of i129G1 on COLO205, previously shown to be a high-binding 9 
cancer cell line for FG129 (9). The i129G1 displayed significantly improved (compared to 129hIgG1), 10 
dose-dependent inhibition of proliferation (Fig. 6, Panel A and Table 1), with an EC50 of 45.6 nmol/L, 11 
as well as a significantly improved, but more modest, PI uptake (Fig. 6, Panel B).  In comparison, 12 
negligible direct cytotoxicity was observed on the low to moderate binding ASPC1 or BXPC3 13 
(Supplementary Fig. 3). Next, we analyzed the avidity of i129G1 using a sialyl Lewis
a
-APD-HSA-14 
coated chip and SPR. The i129G1 mAb exhibited significantly improved avidity compared to 15 
129hIgG1 (Fig. 6, panel C, Table 1 and Supplementary Fig. 2), resulting predominantly from an 16 








 for 129hIgG1 and i129G1, 17 
respectively). On COLO205, i129G1 maintained ADCC activity in the nanomolar range (EC50 2.4 18 
nmol/L), compared to 1.7 nmol/L for 129hIgG1, but the overall percentage lysis was significantly 19 
reduced (Fig. 6, panel D, Table 1). The CDC activity of i129G1, however, was significantly increased 20 
compared to the parental 129hIgG1, with EC50 of 8.2 nmol/L and 75 nmol/L, respectively (Fig. 6, 21 
Panel E, Table 1). The direct cytotoxicity as well as improved avidity of i129G1 led us to analyze its 22 
pore-forming ability on COLO205.  The incubation of COLO205 with i129G1, caused the formation of 23 
large cell clumps with uneven surfaces, as well as the appearance of irregular pore-like structures 24 
(Fig. 6, Panel F).  Incubation with 129hIgG1, at the same concentration, also led to a degree of cell 25 
clumping, but smaller and fewer clumps were observed, without evidence of pore formation.  26 
The direct cytotoxicity and improved avidity of i129G1 directed us towards analyzing the in vivo anti-27 
tumor activity of i129G1 in comparison with the parental 129hIgG1 in a COLO205 xenograft model. 28 
The i129G1 mAb instigated a significant reduction in tumor volume compared to vehicle control (two-29 
way ANOVA, P <0.0001, Fig.6, Panel G and Supplementary Fig. 4) which remained significant when 30 
compared to 129hIgG1, thereby corroborating the in vitro results. No adverse effects on mean body 31 
weight were observed (Fig. 6, Panel H).  32 
In order to ascertain that our Fc-engineering approach had not impacted on the biopharmaceutical 33 
development potential of the i129G1 mAb, we evaluated its in vitro FcRn binding ability, as well as its 34 
solution aggregation status using a range of biophysical and biochemical approaches. In vitro binding 35 
of i129G1 to rhFcRn at pH6.0 and pH7.0 was compared to the parental 129hIgG1 as well as clinically 36 
validated Ipilimumab, also a hIgG1.  At pH6.0, 129hIgG1 as well as i129G1 display improved binding 37 
compared to Ipilimumab.  Furthermore, i129G1 exhibited significantly improved rhFcRn binding 38 
compared to 129hIgG1 at the highest concentrations tested (Fig. 6, Panel I).  Some rhFcRn binding 39 
was observed at pH7.0, mainly at the higher concentrations, with the parental 129hIgG1 displaying 40 
higher reactivity compared to i129G1. Next, we evaluated the solution-phase characteristics of 1 
i129G1 compared to the parental 129hIgG1 using SEC-MALS and AUC.  The SEC-MALS profile of 2 
129hIgG1 as well as i129G1 were similar, containing a main peak (16-18mL) consistent with an 3 
antibody monomer as well as two minor peaks corresponding to higher molecular weight (MW) 4 
species (15mL and 8mL (void volume), respectively) (Fig.6, Panel J, i).  AUC profiles of both mAbs 5 
across the three concentrations tested, revealed a slight increase in the number of higher MW 6 
species for i129v1, the main mAb monomer peak being 80.6% ± 2.6% and 67.6% ± 2.3% of all 7 
species detected in the sample for 129hIgG1 and i129v1, respectively (Fig.6, Panel J, ii). The latter 8 
analysis prompted us to investigate whether the small increase in higher molecular weight species in 9 
the i129v1 sample would lead to complement activation in normal human serum in the absence of 10 
antigen engagement.  A commercial C4d detection kit (indicating classical complement pathway 11 
activation) was used and the analysis performed with serum from three healthy donors. Whereas 12 
heat-aggregated (HA) mAb instigated a significant increase in C4d levels upon incubation with human 13 
serum, neither i129G1, nor 129hIgG1 caused significant elevation of C4d above the background 14 
(Fig.6, Panel J, iii). 15 
  16 
Discussion 1 
Whereas unmodified cancer glycan-targeting mAbs often exhibit anti-tumor activity in preclinical 2 
animal models, they perform disappointingly in the clinic (3,22-24). One possible explanation is that 3 
mIgG3 anti-glycan mAbs exhibited direct cytotoxic activity, which was significantly reduced when 4 
chimerized or humanized to hIgG1 (10-13). Similarly, the Lewis
a/c/x 
FG88.2 used in this study, a 5 
mIgG3 isotype, exhibited high avidity as well as direct cytotoxicity upon binding to high target-6 
expressing cancer cells (7), both of which were significantly reduced on chimerization to hIgG1. 7 
 It is perhaps not surprising that the direct cytotoxicity of cancer glycan-targeting mIgG3 mAbs was 8 
reduced upon chimerization to a hIgG1 isotype, in view of the well-documented effect of mAb 9 
constant regions on variable region affinity and specificity (25-30). However, constant region-driven 10 
allosteric effects (intramolecular) tend to be mAb and target specific (27).  Greenspan et al. on the 11 
other hand, surmised that mIgG3 intermolecular cooperativity - enhanced binding through stabilization 12 
of non-covalent interactions between neighbouring bound mAbs - brought about increased avidity for 13 
multivalent antigen and ensuing isotype restriction (18,31,32).  Improved avidity, resulting mainly from 14 
slower kinetic off-rates by mIgG3 mAbs, compared to other isotypes, has also been observed by 15 
others and resulted in more effective binding at high epitope density (33-37). A number of 16 
multimerization strategies with human isotype mAbs have attempted to recreate this increased avidity 17 
for cancer antigens, but these were inefficient or unstable (38-40). Additionally,  a plethora of Fc 18 
engineering strategies, mostly to impact on mAb effector functions (ADCC and CDC), through 19 
modifying FcγR or C1q binding, as well as mAb half-live, via FcRn engagement, have been described 20 
(41,42). Interestingly, crystal packing-induced mAb oligomerization through Fc:Fc interactions in a 21 
number of human mAb isotypes (43-46) formed the basis of a recently described hexameric mAb 22 
platform for improved complement activation (47-49). The aforementioned HexaBody technology 23 
centred on two positions (E345 and E430) the mutation of which significantly enhanced CDC activity, 24 
without impacting on other key pharmacokinetic and biopharmaceutical properties.  Our approach on 25 
the other hand, focused on improving direct cell killing of glycan-targeting mAbs through engineering 26 
increased avidity, mirroring a common ability observed for the murine IgG3 isotype. Advantageously, 27 
there is no requirement for complement or immune effector cells and as such our strategy may be 28 
less susceptible to immune-suppression in the tumor microenvironment.  29 
In the current study we describe the creation of hIgG1 anti-glycan mAbs with increased avidity and 30 
direct cytotoxic activity through the transfer of selected mIgG3 constant region residues. Candidate 31 
residues were identified through screens based on increased direct cytotoxicity and avidity, when 32 
introduced into hIgG1 (gain-of-function), and/or decreased direct cytotoxicity and avidity when 33 
replaced by the respective hIgG1 residues in mIgG3 (loss-of-function), using the Lewis
a/c/x 
FG88.2.  34 
Differences in segmental flexibility between the two mAbs due to the changed CH1 and hinge 35 
regions as well as a direct contribution by murine IgG3 CH1 were ruled out, as the introduction of 36 
murine IgG3 CH1 into 88hIgG1 did not increase direct cytotoxicity.  Neither did the introduction of 37 
hIgG1 CH1 into 88mIgG3 decrease direct cytotoxicity.  The murine IgG3 hinge region has somewhat 38 
greater flexibility, compared to other murine isotypes (50), but an involvement of the hinge region, in 39 
isolation, is unlikely to be solely responsible for the observed direct cytotoxicity and improved avidity, 1 
as was recently shown for an erythrocyte glycan binding mIgG3 mAb (36).  2 
Focusing on the mIgG3 Fc region, a major contribution by CH3 was identified, with effects evident in 3 
improved cytotoxicity as well as avidity, the latter mainly the result of a decreased dissociation rate. A 4 
minor contribution by CH2 was only evident when screened via the loss-of-function approach, 5 
suggesting a less dominant effect.  Similarly, in this setting, the decreased avidity coincided with an 6 
increased dissociation rate. An analogous analysis identified a contribution by both CH2 and CH3 7 
domain in protective mIgG3 mAbs directed at the capsular antigen of Bacilllus anthracis (37). More 8 
recently, Klaus et al. performed a comprehensive evaluation of mIgG3 constant region contributions 9 
to blood glycan avidity (36).   Although they attributed a stronger role for the mIgG3 CH2 domain, an 10 
effect of CH3 domain was also noted and led to the overall conclusion that the increased avidity of the 11 
mIgG3 isotype was likely the result of additive effects through CH domain interplay. 12 
Further dissection of the combined CH2CH3 region through subdomain analysis revealed full regain 13 
of 88mIgG3 direct cytotoxicity by a section, encompassing the CH2CH3 junction (‘elbow’), residues 14 
286-397. This stretch of residues contained the combined effects of the dominant CH3 element 15 
(residues 339-397) as well as the subdominant CH2 contribution (residues 286-345).  Although the 16 
CH3 element (339-397) in isolation led to an improved avidity, as well as cytotoxicity, unfortunately, it 17 
coincided with significantly reduced CDC compared to 88hIgG1. This is likely an indirect, 18 
conformational, effect on C1q binding, as, although close to known C1q interacting residues, none of 19 
the 339-397 residues are directly-interacting (47,51).  It however necessitated the analysis of residues 20 
in the region of 286-397 for further refinement of contributing elements.  21 
The introduction into 88hIgG1 of a discontinuous section comprising residues 286-306 and 339-378, 22 
recapitulated 88mIgG3 cytotoxicity and avidity, whilst maintaining immune effector functions (ADCC 23 
and CDC).  The likely explanation for the greater than anticipated number of mIgG3 residues required 24 
for increased avidity through intermolecular cooperativity is the combined effect of directly interacting 25 
as well as conformational residues, the latter potentially creating a permissive framework.  A role for 26 
charge distribution patterns, notably in CH2, can also not be ruled out, as it has been shown to 27 
enhance mIgG3 binding to negatively charged multivalent antigen and is distinct from hIgG1 (36,37).  28 
The introduction of 26 mIgG3 in hIgG1 may create MHCII binding epitopes that have the potential to 29 
drive HAMA responses in patients. IEDB analysis of the 26 mIgG3 residue-containing hybrid 30 
88hIgG1, revealed two clusters (residues 294-315 and 365-378), one containing several potentially 31 
high-scoring epitopes.  Residues in cluster 1, at positions 294, 300 and 305,  were reverted to human 32 
sequence with maintained avidity and direct cytotoxicity.  On the other hand, reverting residues at 33 
positions 351 and 371 (cluster 2, with weaker binding scores) led to a small but significant decreased 34 
cytotoxicity, hence were maintained in the final construct. Importantly, this superior 88hIgG1 hybrid 35 
mAb, with mIgG3-matching direct cytotoxicity and avidity, induced cellular aggregation, pore formation 36 
and cell lysis on high-binding HCT15, suggesting a similar cell killing mechanism compared to the 37 
parental FG88.2 (7). The pore formation and eventual cell lysis share similar cellular disintegration 38 
features with necroptosis, but cannot be distinguished from necrosis or secondary necrosis (52). The 1 
eventual outcome from the released DAMPs - constitutive or induced as a result of activated stress 2 
pathways – during this inflammatory cell death depends on the cellular environment as well as the 3 
underlying signalling cascades, but collectively have the potential to create an inflammatory 4 
environment that may further enhance immune effector functions and/or instigate an adaptive immune 5 
response through cross-presentation of released tumor antigens (16,53). Advantageously, i88G1 6 
maintained immune effector functions with CDC activity being significantly improved, and ADCC 7 
activity being somewhat reduced, compared to 88hIgG1.  As the Fc residues involved in 8 
FcgammaRIIa/RIIIa binding are predominantly located in the lower hinge and adjacent top of CH2 9 
region, it is unlikely that our introduced changes have a direct effect on this interaction, but we cannot 10 
rule out an indirect effect (54).  11 
Further validation of our approach, came from the introduction of the selected 23 mIgG3 residues 12 
into the sialyl-di-Lewis
a
 targeting 129hIgG1, that has a more favorable normal tissue distribution whilst 13 
targeting a wide range of tumor tissues on tumor microarray analyses, notably binding over 70% of 14 
pancreatic, and over 30% of gastric and colorectal tumor tissues, as well as over 20% of ovarian and 15 
non-small cell lung cancer tumor tissues (9). Interestingly, the hybridoma-produced parental FG129 is 16 
a mIgG1, that lacks direct cytotoxic ability.  Thus, the creation of i129G1 with significantly improved 17 
avidity, through a slower dissociation rate, compared to 129hIgG1, coinciding with nanomolar direct 18 
cell killing ability on COLO205 suggests that our approach may have broader applicability, as well as 19 
being relevant for immunomodulatory mAbs that rely on avidity effects (41). The direct cell killing 20 
exerted by i129G1 manifested itself in a similar manner as for i88G1: mAb-induced cellular 21 
aggregation followed by pore formation and eventual cell lysis. The introduction of the mIgG3 22 
residues into i129G1 mAb had a mixed effect on effector functions: whilst overall ADCC-induced cell 23 
lysis was significantly reduced, i129G1 maintained nanomolar EC50. The CDC activity of i129G1 on 24 
the other hand was significantly increased.  This mirrored the results obtained with i88G1, albeit with 25 
a stronger reduction in ADCC for i129G1, suggesting that the nature of the glycotarget also affects 26 
ADCC potency: whereas the FG88.2 targets glycoproteins as well as glycolipids, the FG129 only 27 
targets glycoproteins. Our improved mAb construct, i129G1 exhibited significant tumor volume 28 
reduction in a COLO205 xenograft model in nude mice. Remarkably, i129G1 displayed effective 29 
tumor control that was significantly better than 129hIgG1, the latter exhibiting no significant tumor 30 
reduction, further emphasizing the value of direct cytotoxic ability.  31 
Additionally, it was important to ascertain that our Fc-engineering had not impacted on the solution 32 
self-association of i129G1. Although the biophysical analysis suggested a small increase in the 33 
proportion of higher MW species in the i129G1 sample, more apparent from AUC than SEC-MALS, 34 
this did not result in a significantly increased C4d generation upon incubation with healthy human 35 
donor serum.  We did not observe a reduction in rhFcRn by i129G1 binding, suggesting that the 36 
pharmacokinetic aspects equally had not been compromised by our Fc-engineering.   37 
The creation of improved cancer glycan targeting mAbs, with enhanced avidity as well as direct 38 
cytotoxicity, through establishing intermolecular cooperativity binding, may lead to superior clinical 39 
utility. Additionally, it is plausible that mAb multimerization upon glycan target engagement through 1 
alternative strategies may equally lead to increased avidity and ensuing direct cytotoxicity. Our 2 
approach may also have value for mAbs targeting cancer-associated proteins, where longer target 3 
residence time may lead to more profound biological effects, but this remains to be validated. 4 
Importantly, reinstating the unusual, proinflammatory cell killing mode observed for many glycan-5 
targeting mIgG3 mAbs, into the hIgG1 framework, opens the door to combination immunotherapy.    6 
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Table 1. Overview of the functional characteristics of the improved constructs  5 
 6 


















88mIgG3 0.3 26.7 ND ND +++ 
88hIgG1 48.3 N/A 0.13 3.9 - 
i88G1 0.5 29.4 0.35 0.1 ++ 
129hIgG1 2.5 N/A 1.7 75.3 - 
i129G1 0.005 45.6 2.4 8.2 ++ 
a
deduced from proliferation inhibition on COLO205 7 
N/A: not appropriate, ND: not determined 8 
b
sensorgrams underlying the avidity determination are shown in Supplementary Fig. 2 9 
 10 
11 
Figure Legends 1 
Figure 1. Maintenance of cancer cell binding, but significantly decreased direct cytotoxicity of 2 
88hIgG1 compared to 88mIgG3 and parental hybridoma mAb, FG88.2 - Comparable HCT15 and 3 
COLO205 cell binding by 88hIgG1, 88mIgG3 and FG88.2 (hybridoma mAb)(Panel A). Significantly 4 
reduced direct cytotoxicity (PI uptake) on HCT15 by 88hIgG1 compared to 88mIgG3 and FG88.2 5 
(Panel B). Significantly reduced proliferation inhibition by 88hIgG1 compared to 88mIgG3 and FG88.2 6 
on COLO205 (Panel C) and HCT15 (Panel D). Significance (88hIgG1 compared to 88mIgG3) 7 
deduced from two-way ANOVA. 8 
Figure 2. mIgG3 CH3 and to a lesser extent CH2 contribute to the direct cytotoxicity and 9 
improved avidity - Constant domain shuffling suggests no significant contribution by CH1 to direct 10 
cytotoxicity (PI uptake, HCT15, Panel A; proliferation inhibition on COLO205, panel B). In contrast, 11 
CH3 (1m3 and 3h3) contributes significantly to direct cytotoxicity, with a minor contribution by mCH2 12 
only evident in a loss-of-function approach (3h2) (PI uptake, HCT15, Panel C; proliferation inhibition, 13 
COLO205, panel D). Significance versus the respective parental constructs was deduced from two-14 
way ANOVA. Significantly increased avidity and decreased off-rate by 1m3; with significantly 15 
decreased avidity and increased off-rate by 3h2 and more pronounced by 3h3, confirming the major 16 
CH3 and minor CH2 contributions (Panel E, F). Significance deduced using one-way ANOVA, with 17 
Dunnett’s corrections for multiple comparisons. 18 
Figure 3. SD286-397 encompassing the CH2:CH3 junction underlies mIgG3 direct cytotoxicity 19 
and improved avidity - Subdomain divisions of CH2CH3 identified two regions that did not 20 
contribute: SD232-294 and SD390-447, as well as two regions that significantly contributed to direct 21 
cytotoxicity and avidity: SD286-345 (CH2) as well as SD339-397 (CH3). Significantly increased PI 22 
uptake by both constructs and the combination (SD286-397) compared to 88hIgG1 on COLO205 23 
(Panel A) and HCT15 (Panel B).  Significantly increased proliferation inhibition by both constructs and 24 
the combination compared to 88hIgG1 on COLO205 (Panel C) and HCT15 (Panel D).  Significance 25 
(Panels A – D) was deduced from two-way ANOVA. Significantly increased avidity (SPR), resulting 26 
mainly from reduced off-rates by SD286-345 and SD339-397, as well as the combination (SD286-27 
397) (Panels E and F, respectively).  Significantly reduced CDC activity (HCT15) by SD339-397 28 
compared to 88hIgG1 (Panel G); maintenance of ADCC activity (COLO205) by the aforementioned 29 
constructs (Panel H). Significance versus respective parental constructs (Panels E-H) was deduced 30 
from one-way ANOVA, with Dunnett’s corrections for multiple comparisons. 31 
Figure 4. Discontinuous regions consisting of 286-306 combined with 339-378 impart direct 32 
cytotoxicity and enhanced avidity, whilst maintaining immune effector functions - Significantly 33 
increased PI uptake (Panel A) and proliferation inhibition (Panel B) by SD339-378 compared to 34 
88hIgG1 on HCT15. Significantly reduced proliferation inhibition by SD307-345 compared to SD286-35 
345, suggesting a contribution by SD286-306 (Panel C). Significantly increased proliferation inhibition 36 
by the combination of SD286-306+339-378 compared to 88hIgG1 on HCT15 (Panel D) and COLO205  37 
(Panel E), as well as PI uptake on COLO205 (Panel F).  Significantly increased avidity (SPR) by 38 
SD339-378 as well as SD286-306+339-378 compared to 88hIgG1 (Panel G). Maintenance of CDC 39 
activity on HCT15 (Panel H) and ADCC on COLO205 (Panel I) by SD339-378 as well as SD286-40 
306+339-378 compared to 88hIgG1. Significance versus respective parental constructs was deduced 41 
from two-way ANOVA (direct cytotoxicity) or one-way ANOVA with Dunnett’s corrections for multiple 42 
comparisons(avidity, and effector functions). 43 
Figure 5. i88G1 with direct cytotoxicity and enhanced avidity, whilst maintaining immune 44 
effector functions, exhibits pore forming ability - Reversion to human sequence of three residues 45 
in IEDB-predicted MHCII binding cluster 1 (Supplementary Fig.1) created the lead candidate i88G1 46 
(DI1). Significantly increased proliferation inhibition on HCT15 (Panel A) and COLO205 (Panel B) by 47 
i88G1 compared to 88hIgG1, now matching 88mIgG3 activity. Significance deduced from two-way 48 
ANOVA. DI2 displayed a consistent reduction in cytotoxicity compared to DI1 (Panel A and B). 49 
Significantly increased avidity (SPR) by i88G1 compared to 88hIgG1, significantly decreased avidity 50 
by DI2 compared to 88mIgG3 (Panel C), one-way ANOVA with Dunnett’s corrections for multiple 51 
comparisons. Significantly reduced, yet remaining subnanomolar,  ADCC (COLO205, Panel D) as 52 
well as, significantly improved CDC (HCT15, Panel E) activity by i88G1 compared to 88hIgG1 (two-53 
way ANOVA). Evidence of cellular detachment, aggregation and pore formation (white arrows point to 1 
irregular pores) by i88G1 on HCT15 (Panel F). 2 
Figure 6. i129G1, derived from a non-cytotoxic mIgG1 mAb, exhibits significant direct 3 
cytotoxicity, enhanced avidity, pore forming ability as well as significant in vivo tumor control 4 
- Significantly increased proliferation inhibition (Panel A) and PI uptake (Panel B) on COLO205 (Panel 5 
A) by i129G1 compared to 129hIgG1. Direct cell killing of low to moderate binding cancer cell lines 6 
was negligible (Supplementary Fig. 3). Significantly increased functional affinity (SPR) by i129G1 7 
compared to 129hIgG1 (Panel C). i129G1 maintains nanomolar ADCC activity on COLO205, but with 8 
significantly reduced overall lysis compared to h129hIgG1 (Panel D). Nanomolar CDC activity by 9 
i129G1 on COLO205 is significantly increased compared to 129hIgG1 (Panel E). Evidence of cellular 10 
detachment, aggregation and pore forming ability by i129G1 on COLO205 using SEM, white arrows 11 
point to irregular pores (Panel F). Significant in vivo tumor control by i129G1 compared to vehicle 12 
control and compared to 129hIgG1 in a COLO205 xenograft model (Balb/c nude mice) (Panel G).  13 
Individual tumor growth curves are shown in Supplementary Fig. 4. No significant effect on mean 14 
body weight during the course of the mouse study (Panel H). Dose-dependent binding of rhFcRn by 15 
i129G1 and 129hIgG1 at pH6.0 (Panel I).  Significantly increased binding by i129G1 compared to 16 
129hIgG1 at the top two concentrations. Negligible binding at pH7.0 by both constructs (Panel I). 17 
Similar SEC-MALS profiles for i129G1 compared to 129hIgG1(Panel J, i). A small increase in higher 18 
MW species is evident in i129G1 compared to 129hIgG1 via AUC (Panel J, ii). No significant increase 19 
in C4d generation upon incubation with human serum by i129G1, compared to 129hIgG1 (Panel J, iii). 20 
Significance versus respective parental constructs was deduced from two-way ANOVA (direct 21 
cytotoxicity, effector functions, rhFcRn binding, in vivo tumor control) or one-way ANOVA (functional 22 
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